Michael Reynolds Farzan, Ph.D.
Title Professor of Pediatrics Institution Boston Children's Hospital Address Children's Hospital
Id
300 Longwood Ave
Boston MA 02115
|
|
Research
The research activities and funding listed below are automatically derived from
NIH ExPORTER and other sources, which might result in incorrect or missing items.
Faculty can
login
to make corrections and additions.
-
R01AI154989
(FARZAN, MICHAEL R.)
Jun 1, 2020 - May 31, 2025
An injectable hydrogel platform for sustained release of eCD4-Ig
Role: Principal Investigator
-
U19AI149646
(FARZAN, MICHAEL R.)
Apr 15, 2020 - Mar 31, 2025
An AAV-mediated functional cure and its impact on the reservoir
Role: Principal Investigator
-
R21AI152836
(FARZAN, MICHAEL R.)
Mar 6, 2020 - Feb 28, 2022
Eliciting tyrosine-sulfated neutralizing antibodies recognizing the Env apex
Role: Principal Investigator
-
R01AI129868
(FARZAN, MICHAEL R.)
Aug 16, 2017 - Jul 31, 2022
Optimizing eCD4-Ig for eradication and a functional cure
Role: Principal Investigator
-
R44AI134269
(ALPERT, MICHAEL DAVID)
Aug 1, 2017 - Jul 31, 2021
Development of AAV vectors for long-term expression of eCD4-Ig
Role: Co-Principal Investigator
-
DP1DA043912
(FARZAN, MICHAEL R.)
Apr 1, 2017 - Feb 28, 2022
A safety switch for an effective HIV-1 vaccine
Role: Principal Investigator
-
R44AI124832
(ALPERT, MICHAEL DAVID)
Jun 10, 2016 - Jan 31, 2021
WHICH ISOTYPE OF ECD4-IG MOST EFFECTIVELY SUPPRESSES VIRUS REPLICATION?
Role: Co-Principal Investigator
-
P01AI100263
(FARZAN, MICHAEL R.)
Apr 1, 2012 - Mar 31, 2018
A Gene therapeutic approach to stable suppression of HIV-1 replication
Role: Principal Investigator
-
R37AI091476
(FARZAN, MICHAEL R.)
Dec 1, 2010 - Nov 30, 2025
Therapeutic Use of an Enhanced Form of CD4-Ig
Role: Principal Investigator
-
R01AI091476
(FARZAN, MICHAEL R.)
Dec 1, 2010 - Nov 30, 2015
Therapeutic use of an enhanced form of CD4-Ig
Role: Principal Investigator
-
R01AI080324
(FARZAN, MICHAEL R.)
Apr 25, 2009 - Mar 31, 2014
A double-mimetic inhibitor of HIV-1 entry
Role: Principal Investigator
-
R21AI076082
(FARZAN, MICHAEL R.)
Sep 18, 2007 - Aug 31, 2010
Phage-based selection of tyrosine-sulfated entry inhibitors
Role: Principal Investigator
-
R21AI070070
(FARZAN, MICHAEL R.)
Jun 1, 2006 - May 31, 2009
Toward a new world monkey model of HIV-1 infection
Role: Principal Investigator
-
R01AI061601
(FARZAN, MICHAEL R.)
Jun 1, 2004 - May 31, 2010
STUDIES OF A SARS-CORONAVIRUS RECEPTOR
Role: Principal Investigator
-
R21AI055393
(FARZAN, MICHAEL R.)
May 1, 2003 - Apr 30, 2005
ANTI-GP120 ANTIBODIES RECOGNIZING THE CCR5 BINDIGN SITE
Role: Principal Investigator
-
R01AG018913
(FARZAN, MICHAEL R.)
Aug 1, 2001 - Jul 31, 2005
Characterization of BACE and BACE2 Beta-Secretases
Role: Principal Investigator
-
R21AI047680
(FARZAN, MICHAEL R.)
May 15, 2001 - Apr 30, 2004
HIV GP 120 AND HETEROLOGOUS T CELL HELPER EPITOPES
Role: Principal Investigator
-
R01AI048425
(FARZAN, MICHAEL R.)
Jul 1, 2000 - Mar 31, 2011
Tyrosine Sulfation in HIV-1 and SIV Entry
Role: Principal Investigator
Bibliographic
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.